Alkeus Pharmaceuticals reported that its emerging treatment for Stargardt disease slowed the growth of retinal atrophy – i.e., the area of damage to the retina – by approximately 30 percent per year for patients in its Phase 2 TEASE clinical trial at seven clinical research centers in the US.